Brokers Offer Predictions for RAPP Q1 Earnings

Key Points

• HC Wainwright expects Rapport Therapeutics to report a Q1 2027 loss of $1.63 per share and maintains a “Buy” rating with a $66 price target. Full-year 2027 losses are forecast at $4.09 per share.
• Analyst sentiment is broadly positive, with a consensus “Moderate Buy” rating and average price target of $61.57, despite some recent “Sell” downgrades.
• RAPP shares opened at $47.36, near their 52-week high, while the company’s latest quarterly loss of $1.19 per share missed estimates by $0.07. CEO Abraham Ceesay was among insiders who sold shares recently.

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Free Report) - Stock analysts at HC Wainwright issued their Q1 2027 EPS estimates for Rapport Therapeutics in a research note issued to investors on Wednesday, August 12th. HC Wainwright analyst D. Tsao forecasts that the company will post earnings of ($1.63) per share for the quarter. HC Wainwright has a "Buy" rating and a $66.00 price objective on the stock. The consensus estimate for Rapport Therapeutics' current full-year earnings is ($4.09) per share. HC Wainwright also issued estimates for Rapport Therapeutics' Q2 2027 earnings at ($1.68) EPS, Q3 2027 earnings at ($1.73) EPS and Q4 2027 earnings at ($1.77) EPS.

RAPP has been the subject of several other research reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Rapport Therapeutics in a research note on Friday, July 17th. Wall Street Zen cut Rapport Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 8th. Citigroup reiterated a "market outperform" rating on shares of Rapport Therapeutics in a report on Tuesday, June 2nd. Truist Financial started coverage on shares of Rapport Therapeutics in a research note on Monday, May 18th. They set a "buy" rating and a $56.00 price target on the stock. Finally, BTIG Research restated a "buy" rating and issued a $65.00 price objective on shares of Rapport Therapeutics in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Rapport Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $61.57.

Rapport Therapeutics Stock Down 0.8%

Shares of Rapport Therapeutics stock opened at $47.36 on Friday. The firm has a market cap of $2.27 billion, a PE ratio of -15.58 and a beta of 0.97. Rapport Therapeutics has a 52 week low of $13.86 and a 52 week high of $49.50. The business's fifty day simple moving average is $40.66 and its 200-day simple moving average is $35.20.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.07).

Institutional Investors Weigh In On Rapport Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. KBC Group NV acquired a new position in Rapport Therapeutics in the first quarter valued at $30,000. Meeder Asset Management Inc. purchased a new position in shares of Rapport Therapeutics during the fourth quarter worth about $37,000. Russell Investments Group Ltd. acquired a new stake in shares of Rapport Therapeutics during the third quarter worth about $43,000. State of Wyoming acquired a new stake in shares of Rapport Therapeutics during the second quarter worth about $65,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Rapport Therapeutics by 64.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,316 shares of the company's stock valued at $70,000 after purchasing an additional 905 shares during the last quarter.

Insider Buying and Selling

In other news, CEO Abraham Ceesay sold 28,958 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $48.01, for a total transaction of $1,390,273.58. Following the completion of the sale, the chief executive officer owned 486,108 shares in the company, valued at approximately $23,338,045.08. The trade was a 5.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Rock Ventures V. L.P. Third sold 18,572 shares of the company's stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $40.05, for a total transaction of $743,808.60. Following the completion of the transaction, the insider owned 6,280,525 shares of the company's stock, valued at approximately $251,535,026.25. The trade was a 0.29% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 72,281 shares of company stock valued at $3,269,892 over the last ninety days. 12.48% of the stock is currently owned by corporate insiders.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source